首页> 外文期刊>CPT: Pharmacometrics & Systems Pharmacology >PDUFA VI: It Is Time to Unleash the Full Potential of Model‐Informed Drug Development
【24h】

PDUFA VI: It Is Time to Unleash the Full Potential of Model‐Informed Drug Development

机译:PDUFA VI:是时候释放出模型知情药物开发的全部潜力了

获取原文
           

摘要

With years of experience in modeling and simulation (M&S), and model-informed drug development (MIDD) as one of the goals in Prescription Drug User Fee Act (PDUFA) VI authorization, it is now the right time to apply MIDD for high-impact decisions. Over the past two decades, current applications of MIDD in drug discovery, dose selection, benefit–risk assessment, and labeling have been useful. The value proposition of M&S is acknowledged in the PDUFA VI authorization, which provides an excellent opportunity for industry and regulators to collaborate in further advancing the applications of MIDD, potentially changing drug development paradigms.
机译:凭借多年的建模和仿真(M&S)经验以及基于模型的药物开发(MIDD)作为《处方药使用者费用法》(PDUFA)VI授权的目标之一,现在是将MIDD应用于高剂量药物治疗的最佳时机。影响决策。在过去的二十年中,MIDD在药物发现,剂量选择,获益风险评估和标记等方面的当前应用非常有用。 PDUFA VI授权认可了M&S的价值主张,这为行业和监管机构提供了绝佳的机会,可以合作进一步推进MIDD的应用,从而可能改变药物开发范例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号